Clinical Trial Detail

NCT ID NCT02403271
Title A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Pharmacyclics
Indications

lung non-small cell carcinoma

Her2-receptor negative breast cancer

Her2-receptor positive breast cancer

pancreatic adenocarcinoma

Therapies

Durvalumab + Ibrutinib

Age Groups: adult

Additional content available in CKB BOOST